Beyond ADCs: Antibody-encapsulated drug for targeted cancer therapy
Preclinical investigation of trastuzumab-encapsulated actinomycin D, a HER2-targeted AED, has demonstrated potent antitumor activity across cancer models with varying HER2 expression levels, alongside a favorable toxicity profile in animal models, position AED as a promising next-generation targeted cancer therapy that...